Lactic acid bacteria bacteriostatic composition, bacteriostatic effervescent tablet and application

Abstract

The invention discloses a lactic acid bacteria bacteriostatic composition, a bacteriostatic effervescent tablet and application. The lactic acid bacteria bacteriostatic composition is prepared from the following raw materials in parts by weight: 15 to 30 parts of lactic acid bacteria powder, 10 to 16 parts of colistin, 5 to 8 parts of niclosamide, 0.8 to 1 part of polyhexamethylene biguanide hydrochloride and 39 to 66 parts of auxiliaries. The traditional Chinese medicine composition has obvious anti-inflammatory and bacteriostatic effects, has a remarkable treatment effect on vaginitis, can increase the permeability of outer membranes of germs, destroy the integrity of cell membranes and inhibit the activity of an efflux pump at the same time, drugs cannot be discharged by the efflux pump, the accumulation concentration of intracellular drugs is increased, bacterial death is caused, and a large amount of active oxygen of the germs is induced to be synthesized, so that the effect of treating the vaginitis is achieved. Oxidative damage of thalli is accelerated, normal physiological activities are affected, bacterial death is caused, and the relative expression quantity of inflammatory factors can be reduced, so that the antibacterial activity is enhanced.

Description

Technical Field

[0001] The present invention relates to the field of medical pharmaceuticals, and particularly to a lactic acid bacteria antibacterial composition, an antibacterial effervescent tablet and applications thereof. Background Art

[0002] Gynecological inflammation refers to the inflammation of the female reproductive system. Inflammation is the reaction of the body's struggle against pathogens invading the body, and it is a common and multiple disease in gynecology. Clinically common gynecological inflammations mainly include vulvitis, vaginitis, cervicitis, Bartholin gland inflammation, adnexitis, pelvic inflammation, etc. The main manifestations are lower abdominal pain, distension, increased leucorrhea with abnormal odor, abdominal pain during menstruation and increased menstrual volume, etc. Acute inflammation will also present systemic infection symptoms such as persistent high fever and pelvic abscess.

[0003] For the treatment of gynecological inflammation, for example, the treatment of vaginitis, ordinary antibiotics are usually used, but it is prone to rebound phenomenon, with large adverse reactions and increasing drug resistance. Therefore, agents derived from natural products with broad-spectrum antibacterial activity and low drug resistance have gradually become a research hotspot. In daily life, common ones include Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa and Candida albicans, etc. Among them, Candida albicans is the main cause of female vaginitis. The pathogen Staphylococcus aureus can secrete enterotoxin that can cause acute gastroenteritis. Escherichia coli is a common bacterium living in our intestines and is a source of human infection, while Pseudomonas aeruginosa is a common bacterial infection in wounds.

[0004] Lactic acid bacteria are a general term for a class of bacteria that can produce a large amount of lactic acid by utilizing fermentable carbohydrates. These bacteria are widely distributed in nature and have rich species diversity. They are not only ideal materials for studying classification, biochemistry, genetics, molecular biology and genetic engineering, and have important academic value in theory, but also have extremely high application value in important fields closely related to human life such as industry, agriculture, animal husbandry, food and medicine. Regarding the antibacterial performance of lactic acid bacteria, many organic acids will be produced during their metabolism, mainly including lactic acid and acetic acid, and there are also some short-chain fatty acids. When lactic acid bacteria produce a large amount of organic acids, the pH value of the whole system will decrease, and a large number of H + will enter the cell membrane of pathogenic bacteria, acidifying their cytoplasm, thus causing the pathogenic bacteria to be unable to grow normally, thereby achieving the inhibition of the growth of pathogenic bacteria. At the same time, lactic acid bacteria can also produce some bacteriocins. Bacteriocins are some peptide substances with the ability to antagonize or kill pathogenic bacteria, and lactic acid bacteria can produce H2O2 under specific conditions. When H2O2 exists in the environment, superoxide anions will form destructive hydroxyl free radicals. This process can cause the oxidation of lipids on the cell membrane, thereby increasing the permeability of the cell membrane, thus achieving the purpose of sterilization. However, for pure lactic acid bacteria, its antibacterial effect is not strong and may not achieve the expected antibacterial effect.

[0005] Therefore, there is an urgent need for a lactic acid bacteria antibacterial composition that can enhance the antibacterial effect and effectively improve the inflammatory response. Summary of the Invention In response to the problems of the prior art, the present invention proposes a lactic acid bacteria antibacterial composition, an antibacterial effervescent tablet and an application thereof. The lactic acid bacteria antibacterial composition has obvious anti-inflammatory and antibacterial effects and has a significant therapeutic effect on vaginitis. It can increase the outer membrane permeability of pathogens, destroy the integrity of cell membranes, and inhibit the activity of efflux pumps. Drugs cannot be excreted by efflux pumps, and the intracellular drug accumulation concentration increases, leading to bacterial death. In addition, by inducing the large-scale synthesis of active oxygen in pathogens, oxidative damage to the bacteria is accelerated, affecting normal physiological activities and leading to bacterial death. It can also reduce the relative expression of inflammatory factors to enhance antibacterial activity.

[0006] A lactic acid bacteria antibacterial composition comprises the following raw materials in parts by weight: 15-30 parts of lactic acid bacteria powder, 10-16 parts of colistin, 5-8 parts of niclosamide, 0.8-1 part of polyhexamethylene biguanide hydrochloride, and 39-66 parts of an auxiliary agent.

[0007] The lactic acid bacteria antibacterial composition proposed in the present invention has obvious anti-inflammatory and antibacterial effects and a significant therapeutic effect on vaginitis. It can increase the outer membrane permeability of pathogens, destroy the integrity of cell membranes, and inhibit the activity of efflux pumps. Drugs cannot be excreted by efflux pumps, and the concentration of intracellular drug accumulation increases, leading to bacterial death. In addition, by inducing the large-scale synthesis of active oxygen in pathogens, oxidative damage to the bacteria is accelerated, affecting normal physiological activities and leading to bacterial death. It can also reduce the relative expression of inflammatory factors to enhance antibacterial activity.

[0008] In addition, the lactic acid bacteria antibacterial composition provided by the present invention may also have the following additional technical features: Preferably, the lactic acid bacteria antibacterial composition comprises the following raw materials in parts by weight: 20 parts of lactic acid bacteria powder, 14 parts of colistin, 7 parts of niclosamide, 1 part of polyhexamethylene biguanide hydrochloride, 12 parts of effervescent agent, and 53 parts of auxiliary agent.

[0009] Preferably, the auxiliary agent includes 6-10 parts of suspending agent, 3-6 parts of wetting agent, 20-30 parts of filler, and 10-20 parts of deflocculant.

[0010] Preferably, the suspending agent is hypromellose, the wetting agent is poloxamer 188, the filler is lactose, and the deflocculant is sodium tartrate.

[0011] The present invention also provides a lactic acid bacteria antibacterial effervescent tablet, which comprises the above-mentioned lactic acid bacteria antibacterial composition and auxiliary materials.

[0012] In addition, the lactic acid bacteria antibacterial effervescent tablets provided by the present invention may further have the following additional technical features: Preferably, the excipients include anhydrous citric acid and sodium bicarbonate.

[0013] The present invention also provides an application of the lactic acid bacteria antibacterial composition as described above in the preparation of drugs for inhibiting gynecological inflammation.

[0014] The additional aspects and advantages of the present invention will be partially given in the following description, partially become apparent from the following description, or be understood through the practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings in the following description are only some embodiments of the present invention. For those of ordinary skill in the art, other drawings can be obtained based on these drawings without creative efforts.

[0016] Figure 1 It is a pathological morphological change diagram of the vaginal mucosa tissue of each group of rats provided by the embodiments of the present invention.

[0017] The embodiments of the present invention will be further described below with reference to the drawings. DETAILED DESCRIPTION OF THE EMBODIMENTS

[0018] In order to make the objectives, features, and advantages of the present invention more obvious and understandable, the specific embodiments of the present invention will be described in detail below with reference to the embodiments. Several embodiments of the present invention are given in the embodiments. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the disclosure of the present invention more thorough and comprehensive.

[0019] Example 1 In Example 1 of the present invention, a lactic acid bacteria antibacterial composition is provided. The lactic acid bacteria antibacterial composition includes the following raw materials in parts by weight: 15 - 30 parts of lactic acid bacteria powder, 10 - 16 parts of colistin, 5 - 8 parts of niclosamide ethanolamine, 0.8 - 1 part of polyhexamethylene biguanide hydrochloride, and 39 - 66 parts of auxiliary agent; Specifically, the lactic acid bacteria antibacterial composition includes the following raw materials in parts by weight: 20 parts of lactic acid bacteria powder, 14 parts of colistin, 7 parts of niclosamide ethanolamine, 1 part of polyhexamethylene biguanide hydrochloride, 12 parts of effervescent agent, and 53 parts of auxiliary agent.

[0020] Among them, the lactic acid bacteria in the lactic acid bacteria powder are specifically Lactobacillus; In this embodiment, the adjuvant includes 6-10 parts of suspending agent, 3-6 parts of wetting agent, 20-30 parts of filler, and 10-20 parts of deflocculant.

[0021] In this embodiment, the suspending agent is hydroxypropyl methylcellulose, the wetting agent is poloxamer 188, the filler is lactose, and the deflocculant is sodium tartrate alcohol; Specifically, the addition amounts of the adjuvants are as follows: 8 parts of hydroxypropyl methylcellulose, 5 parts of poloxamer 188, 25 parts of lactose, and 15 parts of sodium tartrate alcohol.

[0022] Example 2 Example 2 of the present invention provides a lactic acid bacteria antibacterial effervescent tablet, which includes the lactic acid bacteria antibacterial composition as described in Example 1 and excipients; In this embodiment, the excipients include anhydrous citric acid and sodium bicarbonate; The preparation method of the lactic acid bacteria antibacterial effervescent tablet is as follows: First, the lactic acid bacteria antibacterial composition described in Example 1 is crushed and sieved, and then anhydrous citric acid and sodium bicarbonate are added to a pulverizer for crushing. After thorough mixing, it is sent to a tabletting machine for tabletting to obtain the lactic acid bacteria antibacterial effervescent tablet.

[0023] Example 3 Example 3 of the present invention provides an application of a lactic acid bacteria antibacterial composition in the preparation of a drug for inhibiting gynecological inflammation.

[0024] In order to further illustrate the performance of the lactic acid bacteria antibacterial composition and the lactic acid bacteria antibacterial effervescent tablet provided in the above embodiments of the present invention, a series of experiments are conducted on them, and the experiments are as follows: I. Evaluation experiment 1. Quality evaluation Sedimentation volume ratio: Take 2 g of the sample and place it in a stoppered graduated cylinder. Add 50 mL of water and shake vigorously for 1 min to ensure that the drug particles are fully suspended. At this time, record the initial height H0 of the suspension. Let it stand for 3 h to allow the particles in the suspension to settle naturally, and record the final height H of the suspension. The sedimentation volume ratio = H / H0; Redispersibility: First, pour the sedimented suspension that has been standing for several days into a graduated cylinder. Subsequently, rotate the graduated cylinder 180° and let it stay for 5 s. This operation is recorded as 1 shake, and record the total number of shakes required to achieve the redispersion effect; Loss on drying: Take 1 g of the sample, place it in a weighing bottle, and weigh it precisely. Then place the weighing bottle in an oven set at 105°C for drying until the sample reaches a constant weight state. Calculate the loss on drying by comparing the weight difference before and after drying; Evaluation results: The surface of the sample presented a light yellowish white color, with uniform color and delicate surface; the inspection result showed that the dispersion times were 1 - 2 times, indicating good dispersion performance; after precise measurement, the drying loss of the sample was 1.3%, lower than the specified limit of weight loss of 2.0%, meeting the requirements; the actual sedimentation volume ratio result of the sample was 1, not lower than 0.9, meeting the requirements.

[0025] 2. Precision, stability, and repeatability tests Precision: The chromatographic conditions were an Agilent C18 column, the detection wavelength of the ultraviolet detector was 330 nm, the column temperature was set at 30 °C, the flow rate was set at 1 mL / min, the mobile phase was methanol: water (0.1% formic acid) = 85:15, and the injection volume was 5 μL. According to the above chromatographic conditions, the sample solution was injected repeatedly 6 times, and the precision was calculated. Stability: The sample solution was taken and injected for determination at 0 h, 2 h, 4 h, 8 h, 12 h, and 24 h respectively to detect its stability. Repeatability: Different batches of samples were taken, and 6 sample solutions were prepared respectively by strictly following the same operation steps and conditions, and then injected respectively to detect the repeatability. Results: When the sample solution was injected repeatedly 6 times, the calculated RSD value of precision was 0.12%, far less than the specified value, indicating good precision. When the sample solution was taken and injected for determination at 0 h, 2 h, 4 h, 8 h, 12 h, and 24 h respectively, the calculated RSD value was 2.26%, indicating good stability within 24 h. When different batches of samples were taken and 6 test solution samples were prepared and injected respectively, the calculated RSD value was 0.97%, indicating good repeatability.

[0026] 3. Sample stability experiment An appropriate amount of effervescent tablet samples were taken and placed in a light box equipped with fluorescent lamps or other suitable light containers for irradiation for 10 d, with an illuminance of 4500 ± 500 Lx. Then they were placed in a sealed and clean container and tested at a temperature of 60 °C for 10 d. They were also placed in a constant humidity and airtight container and tested at a temperature of 25 °C and a relative humidity of 90 ± 5% for 10 d. Samples were taken for inspection at 5 and 10 d of the test respectively. After the effervescent tablet samples were tested for 10 d under the conditions of an illuminance of 4500 ± 500 Lx, a temperature of 60 °C, a temperature of 25 °C, and a relative humidity of 90 ± 5%, the drug showed caking and a decrease in content, and the dispersion rate was slow after adding water, and the suspension state was damaged.

[0027] II. In vitro pharmacodynamic experiments 1. Experimental materials Sixty female SD rats were selected, SPF grade, with a body weight of 170 - 190 g. The 60 female SD rats were fed adaptively for one week.

[0028] 2. Rat Model Establishment Sixty female SD rats were subjected to adaptive feeding for one week and then randomly divided into 6 groups using the randomized block method, with 10 rats in each group, namely blank group, model group, high-dose group, medium-dose group, low-dose group, and positive group. Except for the blank group, the models were established in the remaining groups of rats. Each rat was subcutaneously injected with estradiol benzoate injection 2 mg·kg-1, once every 2 days for 3 consecutive times to induce pseudoestrus in the rats. Starting the next day, each rat was subcutaneously injected with hydrocortisone 60 mg·kg-1, once a day for 3 consecutive days to induce immunodeficiency in the rats. Afterwards, the three prepared bacterial suspensions (Escherichia coli, Candida albicans, and Staphylococcus aureus) were mixed in a ratio of 1:1:1. A 1 ml syringe was connected to a gavage needle, and 0.2 ml of the bacterial suspension was drawn up and injected into the vagina every other day for a total of 3 times. After the injection, a cotton ball was inserted into the vaginal opening to prevent the bacterial liquid from flowing out. 24 hours after the third infection, vaginal secretions were dipped with a sterile cotton swab and smeared on the surface of nutrient agar plates and Sabouraud glucose agar plates respectively. After routine culture for 24 hours, bacterial colonies of varying sizes were visible on the plates by naked eye, indicating that the infection was successful.

[0029] The high-dose, low-dose, medium-low-dose, and low-dose groups corresponded to the antibacterial effervescent tablets in the above examples, with dosages of 2 μg / ml, 1 μg / ml, and 0.5 μg / ml, respectively. The positive group was given compound metronidazole vaginal suppositories 0.4 g·kg-1, administered by intravaginal instillation once a day for one week.

[0030] 3. Rat weight detection After administration to each group, the body weight of the rats was measured. The results are shown in Table 1 below: Table 1 Body weight of rats in each group

[0031] As shown in Table 1, observations of the rats' health during the modeling period revealed decreased activity, decreased appetite, erected hair, huddling, tremors in the lower body, and irritability. At the end of the final modeling period, the rats' vulvas were red, swollen, and exude purulent secretions. In terms of body weight, the model group showed little weight gain. However, after the end of dosing, the high- and medium-dose groups showed a significant increase in body weight.

[0032] 4. Pathological testing The vaginal mucosal tissues of rats in each group were immediately fixed in 10% formalin, embedded in paraffin, and cross-sectioned. The pathological morphological changes of vaginal mucosal tissues were observed under a 200x light microscope with HE staining. Figure 1 As shown; from Figure 1As can be seen in the blank group, the vagina was lined with squamous epithelium, with tightly packed epithelial cells and normal morphology. Numerous necrotic cell debris was observed in the intestinal lumen, which is considered a product of cyclical changes in the vaginal epithelium and not caused by pathological changes. The lamina propria was rich in collagen and tightly packed, with very few scattered inflammatory infiltrates. In the model group, the vagina was lined with squamous epithelium, with tightly packed epithelial cells and a small number of neutrophils, which is a normal phenomenon in the cyclical changes of the vaginal epithelium. The lamina propria was edematous, with loosely packed connective tissue and a large number of scattered inflammatory cell infiltrates. Compared with the blank group, the inflammatory response was significantly aggravated. In the high- and medium-dose groups, the vagina was lined with squamous epithelium, with tightly packed epithelial cells and a small number of neutrophils, which is a normal phenomenon in the cyclical changes of the vaginal epithelium. The lamina propria was rich in collagen and tightly packed, with very few scattered inflammatory infiltrates.

[0033] 5. Bacterial load Appropriate amounts of mouse vaginal epithelial tissue were excised and weighed, placed in sterile PBS buffer, and ground into a homogenate. The vaginal epithelial tissue homogenate was diluted serially with sterile PBS and evenly spread onto LB solid culture medium. The culture medium was then incubated overnight at 37°C in a constant-temperature incubator. The number of bacterial colonies on each plate was recorded the following day. The results are shown in Table 2: Table 2 Bacterial colony count

[0034] As can be seen from Table 2, after administration, the bacterial load was significantly reduced compared with the model group. At the same time, the difference in the decrease in bacterial load between the positive group and each dose group was large, and the decrease in bacterial load between different dose groups was not very obvious, but the high-dose group had the largest decrease in bacterial load.

[0035] According to the above experiments, each dosage group has a significant inhibitory effect on pathogens. The reason is that the antibacterial composition provided by the present application can increase the permeability of the outer membrane of pathogens, destroy the integrity of the cell membrane, and at the same time inhibit the activity of the efflux pump. The drug cannot be excreted by the efflux pump, and the concentration of intracellular drug accumulation increases, leading to bacterial death. In addition, by inducing the synthesis of a large amount of reactive oxygen species in pathogens, oxidative damage to the bacteria is accelerated, affecting normal physiological activities, leading to bacterial death. It can also reduce the relative expression of inflammatory factors to enhance antibacterial activity.

[0036] 3. Component Experiment At the same time, in order to further illustrate the effectiveness of the prescription provided in Example 1 of the present invention, the following experimental group and control group are provided: Experimental Group 1: The prescription provided in Experimental Group 1 is exactly the same as that provided in Example 1; Experimental Group 2: The formula provided in Experimental Group 2 is substantially the same as that provided in Example 1, except that the lactic acid bacteria powder in Experimental Group 2 is 15 portions; Experimental Group 3: The prescription provided by Experimental Group 3 is substantially the same as the prescription provided in Example 1, except that the lactic acid bacteria powder in Experimental Group 3 is 30 parts; Experimental Group 4: The prescription provided by Experimental Group 4 is substantially the same as the prescription provided in Example 1, except that the colistin in Experimental Group 4 is 10 parts; Experimental Group 5: The prescription provided by Experimental Group 5 is substantially the same as the prescription provided in Example 1, except that the colistin in Experimental Group 5 is 16 parts; Experimental Group 6: The prescription provided by Experimental Group 6 is substantially the same as the prescription provided in Example 1, except that the niclosamide in Experimental Group 6 is 5 parts; Experimental Group 7: The prescription provided by Experimental Group 7 is substantially the same as the prescription provided in Example 1, except that the niclosamide in Experimental Group 7 is 8 parts; Experimental Group 8: The prescription provided by Experimental Group 8 is substantially the same as the prescription provided in Example 1, except that the lactic acid bacteria powder in Experimental Group 8 is 15 parts, the colistin is 10 parts, and the niclosamide is 5 parts; Experimental Group 9: The prescription provided by Experimental Group 9 is substantially the same as the prescription provided in Example 1, except that the lactic acid bacteria powder in Experimental Group 9 is 30 parts, the colistin is 16 parts, and the niclosamide is 8 parts; Control Group 1: The prescription provided by Control Group 1 is substantially the same as the prescription provided in Example 1, except that Control Group 1 does not contain lactic acid bacteria powder; Control Group 2: The prescription provided by Control Group 2 is substantially the same as the prescription provided in Example 1, except that Control Group 2 does not contain colistin; Control Group 3: The prescription provided by Control Group 3 is substantially the same as the prescription provided in Example 1, except that Control Group 3 does not contain niclosamide; Control Group 4: The prescription provided by Control Group 4 is substantially the same as the prescription provided in Example 1, except that Control Group 5 does not contain colistin and niclosamide; Control Group 5: The prescription provided by Control Group 5 is substantially the same as the prescription provided in Example 1, except that Control Group 5 does not contain lactic acid bacteria powder, colistin, and niclosamide; Specifically, the above experimental group and control group were respectively prepared into corresponding finished products, and they were applied to Candida albicans for a cell bacteriostatic experiment. The experimental process was as follows: The above experimental group and control group were prepared into corresponding samples. Candida albicans was taken and placed in a culture dish, and activated and cultured in a 28 °C environment using Sabouraud dextrose agar medium until Candida albicans covered 80% of the entire culture dish area. Then, a certain amount of the cultured Candida albicans was taken and placed in a container containing a certain amount of sterile sodium chloride solution, and it was diluted to a Candida albicans suspension with a concentration of 5.0x10 6 CFU / mL using a 10-fold serial dilution method. The samples prepared from the above experimental group and control group were incorporated into PBS buffer to prepare corresponding high-concentration bacteriostatic solutions. Then, 20 μL of the high-concentration bacteriostatic solutions corresponding to each group was aspirated and placed in a petri dish containing the Candida albicans suspension, evenly spread with a bacterium spreading rod and left standing for 15 min. The culture medium petri dish was inverted and cultured in an incubator at 28 °C for 1 d. Then, colony counting was performed on each group, and the corresponding bacteriostatic results were determined based on the number of surviving colonies and the number of colonies before adding the bacteriostatic solution. The experimental results are shown in Table 3 below: Table 3 Results of cell bacteriostatic test

[0037] According to the above experimental results, it can be seen that the highest bacteriostatic rate of the prescription provided in Example 1 of the present application against Candida albicans is 92%. From the experimental groups 2-9 and the control groups 1-4, it can be seen that an increase or decrease in the content of each component in the lactic acid bacteria powder, colistin, and niclosamide ethanolamine salt will affect the bacteriostatic rate. At the same time, it can be known that the effect of the change in the content of lactic acid bacteria powder on the bacteriostatic rate is greater than the effect of the change in the content of colistin and niclosamide ethanolamine salt on the bacteriostatic rate. This is because lactic acid bacteria powder can adjust the vaginal environment and effectively inhibit the growth of inflammatory bacteria; colistin mainly binds to phosphate residues, and this binding can replace Ca 2+ and Mg 2+As these ions are replaced, the permeability barrier of the bacterial cell membrane is destroyed, resulting in an imbalance in the balance of ions inside and outside the bacteria, leakage of cytoplasmic proteins, and ultimately cell lysis; niclosamide has the effect of inhibiting the activity of efflux pumps. When the efflux pump gene is missing or the activity is inhibited, the drug cannot be excreted by the efflux pump, and the intracellular drug accumulates, and the concentration increases, leading to bacterial death. It has a synergistic effect with colistin, which can accelerate the oxidative damage of the bacteria by inducing the synthesis of a large amount of active oxygen in the pathogen, affecting normal physiological activities, and leading to bacterial death. If the content of lactic acid bacteria powder, colistin, and niclosamide is too low, the optimal antibacterial effect cannot be achieved. If the content of lactic acid bacteria powder, colistin, and niclosamide is too high, it will affect the vaginal environment and thus affect the antibacterial rate. Lactic acid bacteria powder, colistin, and niclosamide have a synergistic effect. Compared with the prescription of a single component, the mixture of lactic acid bacteria powder, colistin, and niclosamide can enhance the corresponding inhibitory effect. According to the control group 5, its antibacterial rate is 30%, which is due to the antibacterial effect brought by polyhexamethylene biguanide hydrochloride itself; In summary, the lactic acid bacteria antibacterial composition provided by the present invention has obvious anti-inflammatory and antibacterial effects, and has a significant therapeutic effect on vaginitis. It can increase the outer membrane permeability of pathogens, destroy the integrity of the cell membrane, and at the same time inhibit the activity of efflux pumps. The drugs cannot be excreted by the efflux pumps, and the intracellular drug accumulation concentration increases, leading to bacterial death. It also induces the synthesis of a large amount of active oxygen in pathogens, accelerates oxidative damage to the bacteria, affects normal physiological activities, and leads to bacterial death. It can also reduce the relative expression of inflammatory factors to enhance antibacterial activity.

[0038] The above-described embodiments merely illustrate several implementations of the present invention, and while their descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the present invention. It should be noted that a person skilled in the art would be able to make numerous variations and improvements without departing from the spirit of the present invention, all of which fall within the scope of protection of the present invention. Therefore, the scope of protection of the present invention shall be determined by the appended claims.

Claims

1. A lactic acid bacteria antibacterial composition, characterized in that, The lactic acid bacteria antibacterial composition comprises the following raw materials in parts by weight: 15-30 parts of lactic acid bacteria powder, 10-16 parts of colistin, 5-8 parts of niclosamide ethanolamine, 0.8-1 part of polyhexamethylene biguanide hydrochloride, and 39-66 parts of auxiliary agent.

2. The lactic acid bacteria antibacterial composition according to claim 1, characterized in that The lactic acid bacteria antibacterial composition comprises the following raw materials in parts by weight: 20 parts of lactic acid bacteria powder, 14 parts of colistin, 7 parts of niclosamide ethanolamine, 1 part of polyhexamethylene biguanide hydrochloride, 12 parts of effervescent agent, and 53 parts of auxiliary agent.

3. The lactic acid bacteria antibacterial composition according to claim 1, characterized in that, The auxiliary agent comprises 6-10 parts of suspending agent, 3-6 parts of wetting agent, 20-30 parts of filler, and 10-20 parts of deflocculant.

4. The lactic acid bacteria antibacterial composition according to claim 3, characterized in that, The suspending agent is hydroxypropyl methylcellulose, the wetting agent is poloxamer 188, the filler is lactose, and the deflocculant is sodium tartrate.

5. A lactic acid bacteria antibacterial effervescent tablet, which comprises the lactic acid bacteria antibacterial composition as described in any one of claims 1-4 and auxiliary materials.

6. The lactic acid bacteria antibacterial effervescent tablet according to claim 5, wherein The auxiliary materials comprise anhydrous citric acid and sodium bicarbonate.

7. Use of the lactic acid bacteria antibacterial composition as described in any one of claims 1-4 in the preparation of a drug for inhibiting gynecological inflammation.

Images